SCHEMBL5547576

SCHEMBL5547576

CN1CC(c2ccccc2)=C(c2ccccc2)C(c2ccccc2)C1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC6A2 P23975 16/20 0.53
SLC6A3 Q01959 16/20 0.53
SLC6A4 P31645 15/20 0.53
KIF11 P52732 2/20 0.47
RGS12 O14924 1/20 0.47
LMNA P02545 1/20 0.47
CYP1A2 P05177 1/20 0.47
CYP3A4 P08684 1/20 0.47
CYP2D6 P10635 1/20 0.47
ALOX12 P18054 1/20 0.47
NFKB1 P19838 1/20 0.47
HTR2A P28223 1/20 0.47
MAPK1 P28482 1/20 0.47
ADRA1A P35348 1/20 0.47
PTGS2 P35354 1/20 0.47
HRH1 P35367 1/20 0.47
OPRM1 P35372 1/20 0.47
GNAI1 P63096 1/20 0.47
KCNH2 Q12809 1/20 0.47
DRD2 P14416 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5547573 0.80 SLC6A2 (0.35) SLC6A2SLC6A3SLC6A4RGS12LMNA
SCHEMBL28220437 0.72 CFTR (0.44) LMNACYP3A4CYP2D6DRD1
SCHEMBL25778494 0.72 SLC6A2 (0.59) SLC6A2SLC6A3SLC6A4KIF11RGS12
SCHEMBL5542453 0.69 SLC6A2 (0.47) SLC6A2SLC6A3SLC6A4KIF11RGS12
SCHEMBL4032379 0.69 SLC6A2 (1.00) SLC6A2SLC6A3SLC6A4RGS12LMNA
SCHEMBL4466906 0.69 SLC6A2 (0.72) SLC6A2SLC6A3SLC6A4RGS12LMNA
SCHEMBL11618119 0.67 SLC6A2 (0.53) SLC6A2SLC6A3SLC6A4KIF11RGS12
SCHEMBL11245364 0.67 SLC6A2 (0.61) SLC6A2SLC6A3SLC6A4KIF11RGS12
SCHEMBL11640087 0.67 NPC1 (0.62) SLC6A2SLC6A3SLC6A4KIF11RGS12
SCHEMBL28835484 0.66 IGF1R (0.38) SLC6A2SLC6A3SLC6A4PTGS2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2570418-A2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-03-20 EP disclosed
EP-1555267-B1 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES OTSUKA PHARMA CO LTD (JP) 2013-01-16 EP disclosed
US-7262212-B2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-28 US disclosed
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-05-04 US disclosed
EP-1555267-A1 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-07-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles NR2C2, NR4A3, NR4A2 SLC6A2 3396/4885SLC6A3 1944/4885SLC6A4 4191/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.